Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	RNA polymerase II transcription regulatory region sequence-specific DNA binding	CDK9 ZNF410 ZNF793 ZNF134 ZBTB7A ZNF136 ZNF263 ZNF23 ZNF354A ZBTB7C ZNF157 ZNF660 GLIS2 ZNF516 ZNF621 ZNF749 ZNF225 ZNF319 ZNF439 ZNF354B ZBTB1 PRDM14 ZNF614 ZFP62	6.67e-09	1459	86	24	GO:0000977
GeneOntologyMolecularFunction	RNA polymerase II cis-regulatory region sequence-specific DNA binding	CDK9 ZNF410 ZNF793 ZNF134 ZBTB7A ZNF136 ZNF263 ZNF23 ZNF354A ZBTB7C ZNF157 ZNF660 GLIS2 ZNF516 ZNF621 ZNF225 ZNF319 ZNF354B ZBTB1 ZFP62	2.34e-07	1244	86	20	GO:0000978
GeneOntologyMolecularFunction	cis-regulatory region sequence-specific DNA binding	CDK9 ZNF410 ZNF793 ZNF134 ZBTB7A ZNF136 ZNF263 ZNF23 ZNF354A ZBTB7C ZNF157 ZNF660 GLIS2 ZNF516 ZNF621 ZNF225 ZNF319 ZNF354B ZBTB1 ZFP62	3.30e-07	1271	86	20	GO:0000987
GeneOntologyMolecularFunction	DNA-binding transcription factor activity, RNA polymerase II-specific	ZNF793 ZNF134 ZBTB7A ZNF136 ZNF263 ZNF23 ZNF354A ZBTB7C ZNF157 GLIS2 ZNF516 ZNF621 ZNF749 ZNF225 ZNF319 ZNF439 ZNF354B ZBTB1 ZNF614 ZFP62	1.72e-06	1412	86	20	GO:0000981
GeneOntologyMolecularFunction	protein kinase activity	TAOK2 CDK9 BRAF TBCK TNK2 PRKCE IRAK3 CHEK1 MAPK7 MAP2K2 ARAF EPHA1	9.77e-06	600	86	12	GO:0004672
GeneOntologyMolecularFunction	protein serine/threonine kinase activity	TAOK2 CDK9 BRAF TNK2 PRKCE IRAK3 CHEK1 MAPK7 MAP2K2 ARAF	2.17e-05	446	86	10	GO:0004674
GeneOntologyMolecularFunction	kinase activity	TAOK2 CDK9 BRAF TBCK TNK2 PRKCE IRAK3 CHEK1 MAPK7 MAP2K2 ARAF EPHA1 CKMT1A	2.25e-05	764	86	13	GO:0016301
GeneOntologyMolecularFunction	protein serine kinase activity	TAOK2 CDK9 BRAF TNK2 PRKCE CHEK1 MAPK7 MAP2K2 ARAF	2.63e-05	363	86	9	GO:0106310
GeneOntologyMolecularFunction	phosphotransferase activity, alcohol group as acceptor	TAOK2 CDK9 BRAF TBCK TNK2 PRKCE IRAK3 CHEK1 MAPK7 MAP2K2 ARAF EPHA1	5.04e-05	709	86	12	GO:0016773
GeneOntologyMolecularFunction	very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase activity	HACD2 HACD1	1.09e-04	4	86	2	GO:0102158
GeneOntologyMolecularFunction	transferase activity, transferring phosphorus-containing groups	TAOK2 CDK9 BRAF TBCK TNK2 PRKCE IRAK3 CHEK1 MAPK7 MAP2K2 ARAF EPHA1 CKMT1A	1.80e-04	938	86	13	GO:0016772
GeneOntologyMolecularFunction	MAP kinase kinase kinase activity	TAOK2 BRAF ARAF	2.09e-04	27	86	3	GO:0004709
GeneOntologyMolecularFunction	3-hydroxyacyl-CoA dehydratase activity	HACD2 HACD1	5.05e-04	8	86	2	GO:0018812
GeneOntologyMolecularFunction	protein serine/threonine/tyrosine kinase activity	BRAF TNK2 MAP2K2	1.09e-03	47	86	3	GO:0004712
GeneOntologyMolecularFunction	enoyl-CoA hydratase activity	HACD2 HACD1	1.18e-03	12	86	2	GO:0004300
Domain	-	ZNF410 ZNF793 ZNF134 ZBTB7A ZNF136 ZNF263 ZNF23 ZNF354A ZBTB7C ZNF157 ZNF660 GLIS2 ZNF516 ZNF407 ZNF621 ZNF749 ZNF225 ZNF319 ZNF439 ZNF354B ZBTB1 PRDM14 ZNF282 ZNF614 ZFP62	1.87e-16	679	85	25	3.30.160.60
Domain	zf-C2H2	ZNF410 ZNF793 ZNF134 ZBTB7A ZNF136 ZNF263 ZNF23 ZNF354A ZBTB7C ZNF157 ZNF660 GLIS2 ZNF516 ZNF407 ZNF621 ZNF749 ZNF225 ZNF319 ZNF439 ZNF354B ZBTB1 PRDM14 ZNF282 ZNF614 ZFP62	3.01e-16	693	85	25	PF00096
Domain	Znf_C2H2/integrase_DNA-bd	ZNF410 ZNF793 ZNF134 ZBTB7A ZNF136 ZNF263 ZNF23 ZNF354A ZBTB7C ZNF157 ZNF660 GLIS2 ZNF516 ZNF407 ZNF621 ZNF749 ZNF225 ZNF319 ZNF439 ZNF354B ZBTB1 PRDM14 ZNF282 ZNF614 ZFP62	3.11e-16	694	85	25	IPR013087
Domain	Znf_C2H2-like	ZNF410 ZNF793 ZNF134 ZBTB7A ZNF136 ZNF263 ZNF23 ZNF354A ZBTB7C ZNF157 ZNF660 ZFR2 GLIS2 ZNF516 ZNF407 ZNF621 ZNF749 ZNF225 ZNF319 ZNF439 ZNF354B ZBTB1 PRDM14 ZNF282 ZNF614 ZFP62	7.26e-16	796	85	26	IPR015880
Domain	Znf_C2H2	ZNF410 ZNF793 ZNF134 ZBTB7A ZNF136 ZNF263 ZNF23 ZNF354A ZBTB7C ZNF157 ZNF660 ZFR2 GLIS2 ZNF516 ZNF407 ZNF621 ZNF749 ZNF225 ZNF319 ZNF439 ZNF354B ZBTB1 PRDM14 ZNF282 ZNF614 ZFP62	9.50e-16	805	85	26	IPR007087
Domain	ZnF_C2H2	ZNF410 ZNF793 ZNF134 ZBTB7A ZNF136 ZNF263 ZNF23 ZNF354A ZBTB7C ZNF157 ZNF660 ZFR2 GLIS2 ZNF516 ZNF407 ZNF621 ZNF749 ZNF225 ZNF319 ZNF439 ZNF354B ZBTB1 PRDM14 ZNF282 ZNF614 ZFP62	1.04e-15	808	85	26	SM00355
Domain	ZINC_FINGER_C2H2_2	ZNF410 ZNF793 ZNF134 ZBTB7A ZNF136 ZNF263 ZNF23 ZNF354A ZBTB7C ZNF157 ZNF660 GLIS2 ZNF516 ZNF407 ZNF621 ZNF749 ZNF225 ZNF319 ZNF439 ZNF354B ZBTB1 PRDM14 ZNF282 ZNF614 ZFP62	3.97e-15	775	85	25	PS50157
Domain	ZINC_FINGER_C2H2_1	ZNF410 ZNF793 ZNF134 ZBTB7A ZNF136 ZNF263 ZNF23 ZNF354A ZBTB7C ZNF157 ZNF660 GLIS2 ZNF516 ZNF407 ZNF621 ZNF749 ZNF225 ZNF319 ZNF439 ZNF354B ZBTB1 PRDM14 ZNF282 ZNF614 ZFP62	4.21e-15	777	85	25	PS00028
Domain	KRAB	ZNF793 ZNF136 ZNF263 ZNF23 ZNF354A ZNF157 ZNF621 ZNF749 ZNF225 ZNF439 ZNF354B ZNF282 ZNF614	8.08e-09	358	85	13	PS50805
Domain	KRAB	ZNF793 ZNF136 ZNF263 ZNF23 ZNF354A ZNF157 ZNF621 ZNF749 ZNF225 ZNF439 ZNF354B ZNF282 ZNF614	1.16e-08	369	85	13	SM00349
Domain	KRAB	ZNF793 ZNF136 ZNF263 ZNF23 ZNF354A ZNF157 ZNF621 ZNF749 ZNF225 ZNF439 ZNF354B ZNF282 ZNF614	1.20e-08	370	85	13	IPR001909
Domain	KRAB	ZNF793 ZNF136 ZNF263 ZNF354A ZNF157 ZNF621 ZNF749 ZNF225 ZNF439 ZNF354B ZNF282 ZNF614	7.67e-08	358	85	12	PF01352
Domain	zf-C2H2_6	ZNF136 ZNF354A ZNF157 ZNF660 ZNF621 ZNF749 ZNF225 ZNF439 ZNF354B ZNF282 ZFP62	1.80e-07	314	85	11	PF13912
Domain	Prot_kinase_dom	TAOK2 CDK9 BRAF TBCK TNK2 PRKCE IRAK3 CHEK1 MAPK7 MAP2K2 ARAF EPHA1	2.11e-06	489	85	12	IPR000719
Domain	PROTEIN_KINASE_DOM	TAOK2 CDK9 BRAF TBCK TNK2 PRKCE IRAK3 CHEK1 MAPK7 MAP2K2 ARAF EPHA1	2.29e-06	493	85	12	PS50011
Domain	Kinase-like_dom	TAOK2 CDK9 BRAF TBCK TNK2 PRKCE IRAK3 CHEK1 MAPK7 MAP2K2 ARAF EPHA1	6.05e-06	542	85	12	IPR011009
Domain	PROTEIN_KINASE_ATP	TAOK2 CDK9 BRAF TNK2 PRKCE IRAK3 CHEK1 MAPK7 MAP2K2 ARAF EPHA1	7.27e-06	459	85	11	PS00107
Domain	Protein_kinase_ATP_BS	TAOK2 CDK9 BRAF TNK2 PRKCE CHEK1 MAPK7 MAP2K2 ARAF EPHA1	8.50e-06	379	85	10	IPR017441
Domain	Pkinase	TAOK2 CDK9 BRAF TBCK PRKCE IRAK3 CHEK1 MAPK7 MAP2K2 ARAF	8.90e-06	381	85	10	PF00069
Domain	Ser/Thr_kinase_AS	TAOK2 CDK9 BRAF PRKCE IRAK3 CHEK1 MAPK7 MAP2K2 ARAF	3.53e-05	357	85	9	IPR008271
Domain	PROTEIN_KINASE_ST	TAOK2 CDK9 BRAF PRKCE IRAK3 CHEK1 MAPK7 MAP2K2 ARAF	3.94e-05	362	85	9	PS00108
Domain	DAG/PE-bd	BRAF PRKCE ARAF	1.14e-04	21	85	3	IPR020454
Domain	Tyr_Pase-like_PTPLA	HACD2 HACD1	1.22e-04	4	85	2	IPR007482
Domain	PTPLA	HACD2 HACD1	1.22e-04	4	85	2	PF04387
Domain	S_TKc	TAOK2 CDK9 BRAF PRKCE CHEK1 MAPK7 MAP2K2 ARAF	2.29e-04	359	85	8	SM00220
Domain	RBD	BRAF ARAF	3.03e-04	6	85	2	PF02196
Domain	RBD	BRAF ARAF	4.24e-04	7	85	2	SM00455
Domain	RBD_dom	BRAF ARAF	4.24e-04	7	85	2	IPR003116
Domain	RBD	BRAF ARAF	4.24e-04	7	85	2	PS50898
Domain	zf-C2H2_11	ZNF354A ZNF354B	7.22e-04	9	85	2	PF16622
Domain	C1_1	BRAF PRKCE ARAF	2.23e-03	57	85	3	PF00130
Domain	Pkinase_Tyr	BRAF TNK2 ARAF EPHA1	2.86e-03	129	85	4	PF07714
Domain	ZF_DAG_PE_1	BRAF PRKCE ARAF	3.10e-03	64	85	3	PS00479
Domain	ZF_DAG_PE_2	BRAF PRKCE ARAF	3.10e-03	64	85	3	PS50081
Domain	C1	BRAF PRKCE ARAF	3.24e-03	65	85	3	SM00109
Domain	PE/DAG-bd	BRAF PRKCE ARAF	3.39e-03	66	85	3	IPR002219
Domain	Ser-Thr/Tyr_kinase_cat_dom	BRAF TNK2 ARAF EPHA1	3.64e-03	138	85	4	IPR001245
Domain	HEAT_REPEAT	MROH2B MROH7 NIPBL	4.00e-03	70	85	3	PS50077
Domain	ARM-type_fold	ZBTB7C MROH2B ASPM MROH7 APOB NIPBL	4.50e-03	339	85	6	IPR016024
Domain	C2_dom	SYT6 PRKCE PLCD1 TNS1	6.69e-03	164	85	4	IPR000008
Domain	ZnF_U1	ZFR2 ZNF407	7.67e-03	29	85	2	SM00451
Domain	Znf_U1	ZFR2 ZNF407	7.67e-03	29	85	2	IPR003604
Pathway	REACTOME_RNA_POLYMERASE_II_TRANSCRIPTION	CDK9 ZNF793 USP2 ZNF136 ZNF263 GTF2E2 ZNF23 ZNF354A ZNF157 ZNF660 CDC16 ZNF621 ZNF749 DGCR8 CHEK1 ZNF225 ZNF439 ZNF354B ZNF282 GEM ZNF614	1.57e-07	1387	61	21	M734
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_KRAS_NRAS_TO_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	9.05e-06	10	61	3	M47374
Pathway	KEGG_MEDICUS_VARIANT_HRAS_OVEREXPRESSION_TO_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	9.05e-06	10	61	3	M47420
Pathway	KEGG_MEDICUS_REFERENCE_RAC_CDC42_PAK_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	9.05e-06	10	61	3	M47735
Pathway	KEGG_MEDICUS_VARIANT_RET_FUSION_KINASE_TO_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	1.24e-05	11	61	3	M47370
Pathway	KEGG_MEDICUS_VARIANT_TRK_FUSION_KINASE_TO_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	1.24e-05	11	61	3	M47371
Pathway	KEGG_MEDICUS_VARIANT_EML4_ALK_FUSION_KINASE_TO_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	1.65e-05	12	61	3	M47369
Pathway	KEGG_MEDICUS_PATHOGEN_HBV_LHBS_TO_PKC_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	1.65e-05	12	61	3	M47597
Pathway	KEGG_MEDICUS_ENV_FACTOR_METALS_TO_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	1.65e-05	12	61	3	M47815
Pathway	KEGG_MEDICUS_PATHOGEN_HCV_CORE_TO_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	2.14e-05	13	61	3	M47589
Pathway	KEGG_MEDICUS_VARIANT_BCR_ABL_FUSION_KINASE_TO_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	2.71e-05	14	61	3	M47364
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_KIT_TO_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	2.71e-05	14	61	3	M47365
Pathway	KEGG_MEDICUS_VARIANT_DUPLICATION_OR_MUTATION_ACTIVATED_FLT3_TO_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	2.71e-05	14	61	3	M47366
Pathway	KEGG_MEDICUS_VARIANT_AMPLIFIED_PDGFR_TO_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	2.71e-05	14	61	3	M47378
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_EGFR_TO_PLCG_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	2.71e-05	14	61	3	M47383
Pathway	KEGG_MEDICUS_VARIANT_EML4_ALK_FUSION_KINASE_TO_PLCG_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	2.71e-05	14	61	3	M47384
Pathway	KEGG_MEDICUS_VARIANT_MET_OVEREXPRESSION_TO_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	2.71e-05	14	61	3	M47488
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_MET_TO_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	3.38e-05	15	61	3	M47367
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_EGFR_TO_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	3.38e-05	15	61	3	M47375
Pathway	KEGG_MEDICUS_REFERENCE_EGF_EGFR_PLCG_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	3.38e-05	15	61	3	M47382
Pathway	KEGG_MEDICUS_VARIANT_AMPLIFIED_FGFR_TO_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	3.38e-05	15	61	3	M47380
Pathway	KEGG_MEDICUS_REFERENCE_CA2_PYK2_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	3.38e-05	15	61	3	M47592
Pathway	KEGG_MEDICUS_PATHOGEN_HBV_HBX_TO_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	3.38e-05	15	61	3	M47593
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_INACTIVATED_FGF17_TO_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	3.38e-05	15	61	3	M47640
Pathway	KEGG_MEDICUS_VARIANT_IGF2_OVEREXPRESSION_TO_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	3.38e-05	15	61	3	M47485
Pathway	KEGG_MEDICUS_REFERENCE_HGF_MET_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	3.38e-05	15	61	3	M47473
Pathway	KEGG_MEDICUS_REFERENCE_FLT3LG_FLT3_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	3.38e-05	15	61	3	M47474
Pathway	KEGG_MEDICUS_REFERENCE_TGFA_EGFR_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	3.38e-05	15	61	3	M47480
Pathway	KEGG_MEDICUS_VARIANT_EGF_OVEREXPRESSION_TO_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	3.38e-05	15	61	3	M47495
Pathway	KEGG_MEDICUS_REFERENCE_EREG_EGFR_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	3.38e-05	15	61	3	M47496
Pathway	KEGG_MEDICUS_REFERENCE_AREG_EGFR_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	3.38e-05	15	61	3	M47497
Pathway	KEGG_MEDICUS_REFERENCE_KITLG_KIT_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	3.38e-05	15	61	3	M47472
Pathway	KEGG_MEDICUS_PATHOGEN_HCMV_GB_TO_PDGFR_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	3.38e-05	15	61	3	M47535
Pathway	KEGG_MEDICUS_PATHOGEN_HPV_E5_TO_EGFR_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	3.38e-05	15	61	3	M47531
Pathway	KEGG_MEDICUS_REFERENCE_EGF_EGFR_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	4.15e-05	16	61	3	M47363
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_FGFR3_TO_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	4.15e-05	16	61	3	M47373
Pathway	KEGG_MEDICUS_REFERENCE_EGF_ERBB2_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	4.15e-05	16	61	3	M47381
Pathway	KEGG_MEDICUS_REFERENCE_P4_PR_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	4.15e-05	16	61	3	M47804
Pathway	KEGG_MEDICUS_ENV_FACTOR_E2_TO_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	4.15e-05	16	61	3	M47801
Pathway	KEGG_MEDICUS_REFERENCE_IGF_IGF1R_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	4.15e-05	16	61	3	M47483
Pathway	KEGG_MEDICUS_REFERENCE_AGE_RAGE_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	4.15e-05	16	61	3	M47682
Pathway	KEGG_MEDICUS_REFERENCE_PDGF_PDGFR_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	5.02e-05	17	61	3	M47376
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_ABETA_TO_AGE_RAGE_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	5.02e-05	17	61	3	M47684
Pathway	KEGG_MEDICUS_REFERENCE_CXCL12_CXCR4_PKC_ERK_SIGNALING_PATHAWAY	BRAF MAP2K2 ARAF	7.11e-05	19	61	3	M47596
Pathway	KEGG_MEDICUS_ENV_FACTOR_NNK_NNN_TO_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	7.11e-05	19	61	3	M47793
Pathway	WP_INTEGRINMEDIATED_CELL_ADHESION	BRAF MAPK7 MAP2K2 TNS1 ARAF	7.75e-05	102	61	5	M39577
Pathway	WP_INTEGRINMEDIATED_CELL_ADHESION	BRAF MAPK7 MAP2K2 TNS1 ARAF	7.75e-05	102	61	5	MM15830
Pathway	WP_CARDIAC_HYPERTROPHIC_RESPONSE	CDK9 PLA2G2A MAPK7 MAP2K2	9.18e-05	55	61	4	M39685
Pathway	KEGG_MEDICUS_REFERENCE_ACH_CHRN_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	9.70e-05	21	61	3	M47792
Pathway	KEGG_MEDICUS_REFERENCE_E2_ER_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	1.28e-04	23	61	3	M47799
Pathway	KEGG_VASCULAR_SMOOTH_MUSCLE_CONTRACTION	BRAF PLA2G2A PRKCE MAP2K2 ARAF	1.37e-04	115	61	5	M9387
Pathway	WP_NOVEL_JUNDMP1_PATHWAY	BRAF MAP2K2 ARAF	1.66e-04	25	61	3	MM15984
Pathway	REACTOME_SIGNALING_BY_BRAF_AND_RAF1_FUSIONS	BRAF ESRP1 MAP2K2 ARAF	1.76e-04	65	61	4	M38994
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_BRAF_TO_ERK_SIGNALING_PATHWAY	BRAF MAP2K2	1.83e-04	5	61	2	M49016
Pathway	WP_MAPK_CASCADE	BRAF MAP2K2 ARAF	2.34e-04	28	61	3	MM15976
Pathway	KEGG_LONG_TERM_DEPRESSION	BRAF PLA2G2A MAP2K2 ARAF	2.35e-04	70	61	4	M8232
Pathway	REACTOME_NEGATIVE_FEEDBACK_REGULATION_OF_MAPK_PATHWAY	BRAF MAP2K2	2.73e-04	6	61	2	M27559
Pathway	REACTOME_NEGATIVE_FEEDBACK_REGULATION_OF_MAPK_PATHWAY	BRAF MAP2K2	2.73e-04	6	61	2	MM15273
Pathway	WP_MAPK_CASCADE	BRAF MAP2K2 ARAF	3.83e-04	33	61	3	M39594
Pathway	REACTOME_RAF_ACTIVATION	BRAF MAP2K2 ARAF	4.19e-04	34	61	3	M27556
Pathway	REACTOME_ONCOGENIC_MAPK_SIGNALING	BRAF ESRP1 MAP2K2 ARAF	4.31e-04	82	61	4	M27626
Pathway	REACTOME_SIGNALING_BY_RECEPTOR_TYROSINE_KINASES	GABRG2 BRAF ESRP1 TNK2 PRKCE CHEK1 MAPK7 MAP2K2 DNMT1	4.37e-04	532	61	9	M27870
Pathway	REACTOME_RAF_ACTIVATION	BRAF MAP2K2 ARAF	4.57e-04	35	61	3	MM15271
Pathway	KEGG_MEDICUS_REFERENCE_FGF_FGFR_RAS_ERK_SIGNALING_PATHWAY	BRAF MAP2K2 ARAF	4.57e-04	35	61	3	M47379
Pathway	REACTOME_SIGNALING_BY_MRAS_COMPLEX_MUTANTS	BRAF ARAF	5.07e-04	8	61	2	M38999
Pathway	KEGG_MEDICUS_REFERENCE_REGULATION_OF_GF_RTK_RAS_ERK_SIGNALING_MRAS_SHOC2_PP1_HOLOPHOSPHATASE	BRAF ARAF	5.07e-04	8	61	2	M47933
Pathway	REACTOME_MAP2K_AND_MAPK_ACTIVATION	BRAF MAP2K2 ARAF	6.31e-04	39	61	3	MM15272
Pathway	WP_BLADDER_CANCER	BRAF MAP2K2 ARAF	6.80e-04	40	61	3	M39523
Pathway	REACTOME_MAP2K_AND_MAPK_ACTIVATION	BRAF MAP2K2 ARAF	6.80e-04	40	61	3	M27557
Pathway	REACTOME_NEGATIVE_REGULATION_OF_MAPK_PATHWAY	BRAF MAP2K2 ARAF	7.85e-04	42	61	3	MM15274
Pathway	KEGG_BLADDER_CANCER	BRAF MAP2K2 ARAF	7.85e-04	42	61	3	M19096
Pathway	REACTOME_NEGATIVE_REGULATION_OF_MAPK_PATHWAY	BRAF MAP2K2 ARAF	8.41e-04	43	61	3	M27560
Pathway	WP_MICRORNAS_IN_CARDIOMYOCYTE_HYPERTROPHY	CDK9 PLA2G2A MAPK7 MAP2K2	8.79e-04	99	61	4	MM15905
Pathway	REACTOME_SIGNALING_BY_MODERATE_KINASE_ACTIVITY_BRAF_MUTANTS	BRAF MAP2K2 ARAF	9.61e-04	45	61	3	M27623
Pathway	WP_MICRORNAS_IN_CARDIOMYOCYTE_HYPERTROPHY	CDK9 PLA2G2A MAPK7 MAP2K2	1.06e-03	104	61	4	M39625
Pathway	WP_FOCAL_ADHESION	BRAF TNK2 MAPK7 MAP2K2 ARAF	1.27e-03	187	61	5	MM15913
Pathway	KEGG_ENDOMETRIAL_CANCER	BRAF MAP2K2 ARAF	1.47e-03	52	61	3	M19877
Pathway	WP_ESC_PLURIPOTENCY_PATHWAYS	BRAF MAPK7 MAP2K2 ARAF	1.58e-03	116	61	4	MM15863
Pathway	REACTOME_PROLONGED_ERK_ACTIVATION_EVENTS	BRAF MAP2K2	1.62e-03	14	61	2	M622
Pathway	REACTOME_PROLONGED_ERK_ACTIVATION_EVENTS	BRAF MAP2K2	1.62e-03	14	61	2	MM14667
Pathway	WP_EMBRYONIC_STEM_CELL_PLURIPOTENCY_PATHWAYS	BRAF MAPK7 MAP2K2 ARAF	1.63e-03	117	61	4	M39530
Pathway	KEGG_NON_SMALL_CELL_LUNG_CANCER	BRAF MAP2K2 ARAF	1.63e-03	54	61	3	M19818
Pathway	WP_OREXIN_RECEPTOR_PATHWAY	GLIS2 PRKCE PLCD1 MAPK7 MAP2K2	1.71e-03	200	61	5	M48048
Pathway	WP_FRAGILE_X_SYNDROME	GABRG2 BRAF MAP2K2 ARAF	1.85e-03	121	61	4	M39804
Pathway	KEGG_ACUTE_MYELOID_LEUKEMIA	BRAF MAP2K2 ARAF	1.91e-03	57	61	3	M19888
Pathway	WP_MET_IN_TYPE_1_PAPILLARY_RENAL_CELL_CARCINOMA	BRAF MAP2K2 ARAF	2.11e-03	59	61	3	M39750
Pathway	WP_TCA_CYCLE_AND_DEFICIENCY_OF_PYRUVATE_DEHYDROGENASE_COMPLEX_PDHC	PC OGDH	2.13e-03	16	61	2	M39489
Pathway	WP_MAPK_PATHWAY_IN_CONGENITAL_THYROID_CANCER	BRAF MAP2K2	2.13e-03	16	61	2	M39882
Pathway	KEGG_NEUROTROPHIN_SIGNALING_PATHWAY	BRAF IRAK3 MAPK7 MAP2K2	2.14e-03	126	61	4	M16763
Pathway	WP_IRON_METABOLISM_DISORDERS	HFE SLC11A2	2.40e-03	17	61	2	M48053
Pathway	WP_IL9_SIGNALING	CDK9 MAP2K2	2.40e-03	17	61	2	M39644
Pathway	REACTOME_SIGNALING_BY_NTRK1_TRKA	BRAF MAPK7 MAP2K2	2.55e-03	63	61	3	MM14714
Pathway	WP_ENDOMETRIAL_CANCER	BRAF MAP2K2 ARAF	2.55e-03	63	61	3	M39623
Pathway	WP_INHIBITION_OF_EXOSOME_BIOGENESIS_AND_SECRETION_BY_MANUMYCIN_A_IN_CRPC_CELLS	BRAF ARAF	2.70e-03	18	61	2	M39737
Pathway	PID_CD8_TCR_DOWNSTREAM_PATHWAY	BRAF PRKCE MAP2K2	2.78e-03	65	61	3	M272
Pathway	KEGG_GLIOMA	BRAF MAP2K2 ARAF	2.78e-03	65	61	3	M1835
Pathway	WP_PATHWAYS_AFFECTED_IN_ADENOID_CYSTIC_CARCINOMA	CHEK1 MAP2K2 CNTN6	2.78e-03	65	61	3	M39682
Pathway	WP_SEROTONIN_RECEPTOR_467_AND_NR3C_SIGNALING	BRAF MAP2K2	3.00e-03	19	61	2	M39358
Pathway	WP_ACUTE_MYELOID_LEUKEMIA	BRAF MAP2K2 ARAF	3.16e-03	68	61	3	M48322
Pathway	WP_MELANOMA	BRAF MAP2K2 ARAF	3.16e-03	68	61	3	M39811
Pubmed	Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition.	CDK9 BRAF TNK2 PRKCE IRAK3 CHEK1 MAPK7 FBXL2 ARAF EPHA1	2.99e-08	372	86	10	22939624
Pubmed	Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.	BRAF MAP2K2 ARAF	1.45e-07	5	86	3	24746704
Pubmed	Germline gain-of-function mutations in RAF1 cause Noonan syndrome.	BRAF MAP2K2 ARAF	1.45e-07	5	86	3	17603482
Pubmed	Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1.	BRAF MAP2K2 ARAF	2.90e-07	6	86	3	8157000
Pubmed	Selective role for RGS12 as a Ras/Raf/MEK scaffold in nerve growth factor-mediated differentiation.	BRAF MAP2K2 ARAF	8.10e-07	8	86	3	17380122
Pubmed	Essential role of B-Raf in ERK activation during extraembryonic development.	BRAF MAP2K2 ARAF	1.73e-06	10	86	3	16432225
Pubmed	Molecular cloning, chromosomal mapping, and developmental expression of a novel protein tyrosine phosphatase-like gene.	HACD2 HACD1	6.04e-06	2	86	2	10644438
Pubmed	A novel requirement for Janus kinases as mediators of drug resistance induced by fibroblast growth factor-2 in human cancer cells.	BRAF PRKCE	6.04e-06	2	86	2	21625473
Pubmed	Mechanism of increased iron absorption in murine model of hereditary hemochromatosis: increased duodenal expression of the iron transporter DMT1.	HFE SLC11A2	6.04e-06	2	86	2	10077651
Pubmed	Slc11a2 is required for intestinal iron absorption and erythropoiesis but dispensable in placenta and liver.	HFE SLC11A2	6.04e-06	2	86	2	15849611
Pubmed	The 3-hydroxyacyl-CoA dehydratases HACD1 and HACD2 exhibit functional redundancy and are active in a wide range of fatty acid elongation pathways.	HACD2 HACD1	6.04e-06	2	86	2	28784662
Pubmed	Ca2+ channel blockers reverse iron overload by a new mechanism via divalent metal transporter-1.	HFE SLC11A2	6.04e-06	2	86	2	17293870
Pubmed	ERK5 is activated by oncogenic BRAF and promotes melanoma growth.	BRAF MAPK7	6.04e-06	2	86	2	29483645
Pubmed	Characterization of the mouse Kid1 gene and identification of a highly related gene, Kid2.	ZNF354A ZNF354B	6.04e-06	2	86	2	10564808
Pubmed	The RNA-mediated estrogen receptor α interactome of hormone-dependent human breast cancer cell nuclei.	TAOK2 MRPS7 ZBTB7A NEPRO GTF2E2 C18orf21 CDC16 DGCR8 HACD2 TSPYL1 MRPL49 NIPBL ARAF CKMT1A	1.75e-05	1497	86	14	31527615
Pubmed	RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.	BRAF ARAF	1.81e-05	3	86	2	20130576
Pubmed	Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas.	BRAF ARAF	1.81e-05	3	86	2	14688025
Pubmed	Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.	BRAF MAP2K2	1.81e-05	3	86	2	25600339
Pubmed	Expression of raf family proto-oncogenes in normal mouse tissues.	BRAF ARAF	1.81e-05	3	86	2	1690378
Pubmed	Endothelial apoptosis in Braf-deficient mice.	BRAF ARAF	1.81e-05	3	86	2	9207797
Pubmed	Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling.	BRAF ARAF	1.81e-05	3	86	2	23352452
Pubmed	Biochemical characterization of novel germline BRAF and MEK mutations in cardio-facio-cutaneous syndrome.	BRAF MAP2K2	1.81e-05	3	86	2	18413255
Pubmed	Overlapping and specific functions of Braf and Craf-1 proto-oncogenes during mouse embryogenesis.	BRAF ARAF	1.81e-05	3	86	2	10704835
Pubmed	The 3-hydroxyacyl-CoA dehydratase 1/2 form complex with trans-2-enoyl-CoA reductase involved in substrates transfer in very long chain fatty acid elongation.	HACD2 HACD1	1.81e-05	3	86	2	38422897
Pubmed	DMT1 genetic variability is not responsible for phenotype variability in hereditary hemochromatosis.	HFE SLC11A2	1.81e-05	3	86	2	15223008
Pubmed	ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers.	BRAF ARAF	1.81e-05	3	86	2	22926515
Pubmed	Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.	BRAF MAP2K2	1.81e-05	3	86	2	16439621
Pubmed	Is diagnosing cardio-facio-cutaneous (CFC) syndrome still a challenge? Delineation of the phenotype in 15 Polish patients with proven mutations, including novel mutations in the BRAF1 gene.	BRAF MAP2K2	1.81e-05	3	86	2	25463315
Pubmed	B-RafV600E inhibits sodium iodide symporter expression via regulation of DNA methyltransferase 1.	BRAF DNMT1	1.81e-05	3	86	2	25378232
Pubmed	Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.	BRAF MAP2K2	1.81e-05	3	86	2	18060073
Pubmed	Iron overload in adult Hfe-deficient mice independent of changes in the steady-state expression of the duodenal iron transporters DMT1 and Ireg1/ferroportin.	HFE SLC11A2	1.81e-05	3	86	2	14618243
Pubmed	Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation.	BRAF MAPK7	1.81e-05	3	86	2	26959608
Pubmed	The interactome of KRAB zinc finger proteins reveals the evolutionary history of their functional diversification.	ZNF793 ZNF136 ZNF282	2.17e-05	22	86	3	31403225
Pubmed	Activation of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase by G protein and tyrosine kinase oncoproteins.	BRAF ARAF	3.61e-05	4	86	2	8394352
Pubmed	Identification of interaction between MEK2 and A-Raf-1.	MAP2K2 ARAF	3.61e-05	4	86	2	11909642
Pubmed	Protein kinase C (PKC)ζ-mediated Gαq stimulation of ERK5 protein pathway in cardiomyocytes and cardiac fibroblasts.	PRKCE MAPK7	3.61e-05	4	86	2	22232556
Pubmed	Selective activation of MEK1 but not MEK2 by A-Raf from epidermal growth factor-stimulated Hela cells.	BRAF ARAF	3.61e-05	4	86	2	8621729
Pubmed	Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome.	BRAF MAP2K2	3.61e-05	4	86	2	18042262
Pubmed	Aberrant expression of COT is related to recurrence of papillary thyroid cancer.	BRAF ARAF	3.61e-05	4	86	2	25674762
Pubmed	Expression of the DMT1 (NRAMP2/DCT1) iron transporter in mice with genetic iron overload disorders.	HFE SLC11A2	3.61e-05	4	86	2	11159549
Pubmed	Craniofacial and dental development in cardio-facio-cutaneous syndrome: the importance of Ras signaling homeostasis.	BRAF MAP2K2	3.61e-05	4	86	2	22946697
Pubmed	B-Raf protein isoforms interact with and phosphorylate Mek-1 on serine residues 218 and 222.	BRAF ARAF	3.61e-05	4	86	2	7731720
Pubmed	Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.	BRAF MAP2K2	3.61e-05	4	86	2	17704260
Pubmed	Functional characterization of a PROTAC directed against BRAF mutant V600E.	BRAF ARAF	3.61e-05	4	86	2	32778845
Pubmed	Dnmt1N/+ reduces the net growth rate and multiplicity of intestinal adenomas in C57BL/6-multiple intestinal neoplasia (Min)/+ mice independently of p53 but demonstrates strong synergy with the modifier of Min 1(AKR) resistance allele.	PLA2G2A DNMT1	3.61e-05	4	86	2	10919675
Pubmed	Rapid and transient recruitment of DNMT1 to DNA double-strand breaks is mediated by its interaction with multiple components of the DNA damage response machinery.	CHEK1 DNMT1	3.61e-05	4	86	2	20940144
Pubmed	Characterization of four mammalian 3-hydroxyacyl-CoA dehydratases involved in very long-chain fatty acid synthesis.	HACD2 HACD1	3.61e-05	4	86	2	18554506
Pubmed	Cardiofaciocutaneous Syndrome	BRAF MAP2K2	3.61e-05	4	86	2	20301365
Pubmed	Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.	BRAF MAP2K2	3.61e-05	4	86	2	21447798
Pubmed	MEK-ERK inhibition corrects the defect in VLDL assembly in HepG2 cells: potential role of ERK in VLDL-ApoB100 particle assembly.	APOB MAP2K2	3.61e-05	4	86	2	17038630
Pubmed	DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.	CHEK1 DNMT1	3.61e-05	4	86	2	17991895
Pubmed	Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: overlapping clinical manifestations with Costello syndrome.	BRAF MAP2K2	3.61e-05	4	86	2	17366577
Pubmed	Transferrin receptor co-localizes and interacts with the hemochromatosis factor (HFE) and the divalent metal transporter-1 (DMT1) in trophoblast cells.	HFE SLC11A2	6.01e-05	5	86	2	15880641
Pubmed	Genes that modify the hemochromatosis phenotype in mice.	HFE SLC11A2	6.01e-05	5	86	2	10791995
Pubmed	Dnmt1-dependent Chk1 pathway suppression is protective against neuron division.	CHEK1 DNMT1	6.01e-05	5	86	2	28928282
Pubmed	Association of HFE protein with transferrin receptor in crypt enterocytes of human duodenum.	HFE SLC11A2	6.01e-05	5	86	2	9990067
Pubmed	Potent antimyeloma activity of a novel ERK5/CDK inhibitor.	CDK9 MAPK7	6.01e-05	5	86	2	23532886
Pubmed	The zinc finger transcription factor Th-POK regulates CD4 versus CD8 T-cell lineage commitment.	ZBTB7A ZBTB7C	6.01e-05	5	86	2	15729333
Pubmed	The proto-oncoprotein KR-POK represses transcriptional activation of CDKN1A by MIZ-1 through competitive binding.	ZBTB7A ZBTB7C	6.01e-05	5	86	2	21804610
Pubmed	Different Raf protein kinases mediate different signaling pathways to stimulate E3 ligase RFFL gene expression in cell migration regulation.	BRAF ARAF	6.01e-05	5	86	2	24114843
Pubmed	In vivo functions of mitogen-activated protein kinases: conclusions from knock-in and knock-out mice.	BRAF ARAF	6.01e-05	5	86	2	17219248
Pubmed	Multiplexed kinase interactome profiling quantifies cellular network activity and plasticity.	CDK9 BRAF CDC16 TNK2 IRAK3 CHEK1 MAPK7 MAP2K2 TNS1 ARAF	8.42e-05	910	86	10	36736316
Pubmed	Acetylation-Mimic Mutation of TRIM28-Lys304 to Gln Attenuates the Interaction with KRAB-Zinc-Finger Proteins and Affects Gene Expression in Leukemic K562 Cells.	ZNF136 ZNF354A ZNF749 ZNF354B ZNF614	8.94e-05	181	86	5	37372979
Pubmed	RAS signaling dysregulation in human embryonal Rhabdomyosarcoma.	BRAF MAP2K2	9.01e-05	6	86	2	19681119
Pubmed	HACD1, a regulator of membrane composition and fluidity, promotes myoblast fusion and skeletal muscle growth.	HACD2 HACD1	9.01e-05	6	86	2	26160855
Pubmed	Platelet-derived growth factor (PDGF)-induced activation of Erk5 MAP-kinase is dependent on Mekk2, Mek1/2, PKC and PI3-kinase, and affects BMP signaling.	MAPK7 MAP2K2	9.01e-05	6	86	2	27339033
Pubmed	Integrated RAS signaling defined by parallel NMR detection of effectors and regulators.	BRAF ARAF	9.01e-05	6	86	2	24441586
Pubmed	Protein array based interactome analysis of amyloid-β indicates an inhibition of protein translation.	USP2 GTF2E2 SYT6 TSPYL1 MAPK7 MRPL49	1.13e-04	305	86	6	21244100
Pubmed	Signaling pathways triggered by HIV-1 Tat in human monocytes to induce TNF-alpha.	PRKCE PLCD1 MAP2K2	1.16e-04	38	86	3	12482669
Pubmed	Role of cellular iron and oxygen in the regulation of HIV-1 infection.	CDK9 HFE	1.26e-04	7	86	2	23678366
Pubmed	Investigation of gene dosage imbalances in patients with Noonan syndrome using multiplex ligation-dependent probe amplification analysis.	BRAF MAP2K2	1.26e-04	7	86	2	20302979
Pubmed	Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome.	BRAF MAP2K2	1.26e-04	7	86	2	21383153
Pubmed	MEK drives BRAF activation through allosteric control of KSR proteins.	BRAF MAP2K2	1.26e-04	7	86	2	29433126
Pubmed	Inducible expression of (V600E) Braf using tyrosinase-driven Cre recombinase results in embryonic lethality.	BRAF CHEK1	1.26e-04	7	86	2	20002887
Pubmed	Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum.	BRAF MAP2K2	1.26e-04	7	86	2	19206169
Pubmed	Characterization of the DOT1L network: implications of diverse roles for DOT1L.	CDK9 PC NIPBL	1.45e-04	41	86	3	20431927
Pubmed	Identification of signalling proteins interacting with B-Raf in the yeast two-hybrid system.	BRAF MAP2K2	1.68e-04	8	86	2	8668348
Pubmed	Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II.	CDK9 GTF2E2	1.68e-04	8	86	2	23064645
Pubmed	c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma.	BRAF MAP2K2	1.68e-04	8	86	2	21514245
Pubmed	SPOP inhibits BRAF-dependent tumorigenesis through promoting non-degradative ubiquitination of BRAF.	BRAF MAP2K2	1.68e-04	8	86	2	36585710
Pubmed	Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus.	APOB FBXL2	1.68e-04	8	86	2	17784784
Pubmed	A human MAP kinase interactome.	BRAF TNK2 PRKCE MAPK7 MAP2K2 TNS1 ARAF	2.07e-04	486	86	7	20936779
Pubmed	Identification of novel in vivo phosphorylation sites of the human proapoptotic protein BAD: pore-forming activity of BAD is regulated by phosphorylation.	BRAF ARAF	2.15e-04	9	86	2	19667065
Pubmed	AMPK Promotes SPOP-Mediated NANOG Degradation to Regulate Prostate Cancer Cell Stemness.	BRAF ARAF	2.15e-04	9	86	2	30595535
Pubmed	A-raf and B-raf are dispensable for normal endochondral bone development, and parathyroid hormone-related peptide suppresses extracellular signal-regulated kinase activation in hypertrophic chondrocytes.	BRAF ARAF	2.15e-04	9	86	2	17967876
Pubmed	A probability-based approach for high-throughput protein phosphorylation analysis and site localization.	C18orf21 BRAF CDC16 MAP2K2 NIPBL ARAF EPHA1	2.55e-04	503	86	7	16964243
Pubmed	Genetic polymorphisms associated with thrombophilia and vascular disease in women with unexplained late intrauterine fetal death: a multicenter study.	HFE APOB	2.68e-04	10	86	2	14706682
Pubmed	Mouse and human phenotypes indicate a critical conserved role for ERK2 signaling in neural crest development.	BRAF MAP2K2	2.68e-04	10	86	2	18952847
Pubmed	FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2.	BRAF PRKCE	2.68e-04	10	86	2	16810323
Pubmed	Cortical migration defects in mice expressing A-RAF from the B-RAF locus.	BRAF ARAF	2.68e-04	10	86	2	16980614
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	CDK9 BRAF CEP89 PRKCE CHEK1 PC MAP2K2 ARAF DNMT1	2.81e-04	861	86	9	36931259
Pubmed	An atlas of combinatorial transcriptional regulation in mouse and man.	ZNF410 ZNF263 GTF2E2 ZNF23 ZNF354A ZNF407 ZBTB1 PRDM14 DNMT1	3.21e-04	877	86	9	20211142
Pubmed	Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.	ZNF793 USP2 ZNF660 CRTAC1 DGCR8 ZNF439 PC NIPBL PLXNB3 DNMT1 BRWD1	3.25e-04	1285	86	11	35914814
Pubmed	The proto-oncoprotein FBI-1 interacts with MBD3 to recruit the Mi-2/NuRD-HDAC complex and BCoR and to silence p21WAF/CDKN1A by DNA methylation.	ZBTB7A DNMT1	3.28e-04	11	86	2	23658227
Pubmed	The ins and outs of HIV-1 Tat.	CDK9 PLCD1	3.93e-04	12	86	2	21951552
Pubmed	Ubiquitin-dependent regulation of MEKK2/3-MEK5-ERK5 signaling module by XIAP and cIAP1.	USP2 MAPK7	3.93e-04	12	86	2	24975362
Pubmed	Impact of cytosine methylation on DNA binding specificities of human transcription factors.	ZNF410 ZBTB7A ZNF263 ZNF23 ZNF660 GLIS2 ZNF282	4.08e-04	544	86	7	28473536
Pubmed	Targeting of Ras-mediated FGF signaling suppresses Pten-deficient skin tumor.	BRAF MAP2K2	4.63e-04	13	86	2	27799550
Pubmed	Mapping the MOB proteins' proximity network reveals a unique interaction between human MOB3C and the RNase P complex.	CDK9 MRPS7 NEPRO C18orf21 DNMT1 BRWD1	4.77e-04	399	86	6	37536630
Pubmed	ZBTB20 is crucial for the specification of a subset of callosal projection neurons and astrocytes in the mammalian neocortex.	ZBTB7A ZBTB7C ZBTB1	5.21e-04	63	86	3	34351428
Interaction	HSP90AB3P interactions	CDK9 BRAF TNK2 PRKCE MAP2K2 ARAF	3.63e-06	98	85	6	int:HSP90AB3P
Cytoband	5q35.3	ZNF354A RASGEF1C ZNF354B ZFP62	3.21e-05	95	86	4	5q35.3
Cytoband	Ensembl 112 genes in cytogenetic band chr19p13	ZBTB7A ZNF136 ZFR2 STAP2 ZNF439 MAP2K2 DNMT1	7.59e-04	797	86	7	chr19p13
Cytoband	Ensembl 112 genes in cytogenetic band chr5q35	ZNF354A RASGEF1C ZNF354B ZFP62	1.02e-03	235	86	4	chr5q35
Cytoband	19p13.3	ZBTB7A ZFR2 STAP2 MAP2K2	1.06e-03	237	86	4	19p13.3
Cytoband	18q23	ZNF516 ZNF407	1.36e-03	29	86	2	18q23
GeneFamily	Zinc fingers C2H2-type\|ZF class homeoboxes and pseudogenes	ZNF410 ZNF793 ZNF134 ZBTB7A ZNF136 ZNF263 ZNF23 ZNF354A ZBTB7C ZNF157 ZNF660 GLIS2 ZNF516 ZNF407 ZNF621 ZNF749 ZNF225 ZNF319 ZNF439 ZNF354B ZBTB1 PRDM14 ZNF282 ZNF614 ZFP62	8.72e-20	718	60	25	28
GeneFamily	Mitogen-activated protein kinase kinase kinases\|RAF family	TAOK2 BRAF ARAF	6.69e-05	24	60	3	654
GeneFamily	Mitogen-activated protein kinase kinase kinases\|RAF family	BRAF ARAF	1.08e-04	5	60	2	1157
GeneFamily	Maestro heat like repeat containing	MROH2B MROH7	5.84e-04	11	60	2	636
Drug	Dihydrostreptomycin sulfate [5490-27-7]; Up 200; 2.8uM; MCF7; HT_HG-U133A	TAOK2 GABRG2 ZNF134 SLC11A2 ZNF407 PLCD1 DGCR8 MAPK7 TNS1	5.86e-08	197	86	9	2237_UP
Drug	Fluvastatin sodium salt [93957-55-2]; Up 200; 9.2uM; PC3; HT_HG-U133A	TAOK2 ZBTB7A NPY5R ZNF407 PRKCE DGCR8 ZNF225	9.21e-06	195	86	7	6691_UP
Drug	Guanfacine hydrochloride [29110-48-3]; Up 200; 14.2uM; MCF7; HT_HG-U133A	HFE GABRG2 USP2 SLC11A2 ZNF516 PLCD1 MAPK7	9.21e-06	195	86	7	5256_UP
Drug	Gelsemine [509-15-9]; Down 200; 12.4uM; HL60; HT_HG-U133A	USP2 ZBTB7A BRAF TNK2 ZNF749 DGCR8 ZNF225	1.02e-05	198	86	7	2162_DN
Drug	Letrozole [112809-51-5]; Up 200; 14uM; MCF7; HT_HG-U133A	HFE USP2 TNK2 MAPK7 FBXL2 ZNF614 EPHA1	1.05e-05	199	86	7	7336_UP
Drug	Foliosidine [2520-38-9]; Down 200; 13uM; MCF7; HT_HG-U133A	HFE ZBTB7A PLA2G2A PRKCE PLCD1 DGCR8 GEM	1.09e-05	200	86	7	3636_DN
Drug	bathophenanthroline disulfonate	HFE SLC11A2 ARAF	4.08e-05	18	86	3	CID000065368
Drug	Myxococcus xanthus antibiotic TA	CDK9 ARAF	8.42e-05	4	86	2	CID006438547
Drug	Naringenine [480-41-1]; Up 200; 14.6uM; HL60; HT_HG-U133A	SLC11A2 TNK2 MAPK7 TNS1 NIPBL ZNF614	8.43e-05	190	86	6	1342_UP
Drug	Epitiostanol [2363-58-8]; Up 200; 13uM; MCF7; HT_HG-U133A	POMT2 HFE USP2 ZNF516 PRKCE EPHA1	8.68e-05	191	86	6	7342_UP
Drug	Trifluoperazine dihydrochloride [440-17-5]; Down 200; 8.4uM; MCF7; HT_HG-U133A	POMT2 HFE SLC11A2 PRKCE ZBTB1 ZNF614	8.68e-05	191	86	6	5442_DN
Drug	NSC-85245	ASPM CHEK1 EPHA1	8.72e-05	23	86	3	CID000257281
Drug	semustine; Up 200; 100uM; MCF7; HT_HG-U133A	TAOK2 HFE GABRG2 TNK2 ZNF749 GEM	9.46e-05	194	86	6	7487_UP
Drug	Sertaconazole nitrate [99592-39-9]; Down 200; 8uM; MCF7; HT_HG-U133A	TAOK2 ZNF516 DGCR8 ZNF282 ARAF EPHA1	9.46e-05	194	86	6	6811_DN
Drug	Acyclovir [59277-89-3]; Down 200; 17.8uM; MCF7; HT_HG-U133A	POMT2 HFE ZBTB7A SLC11A2 DGCR8 MAPK7	9.46e-05	194	86	6	5278_DN
Drug	Flucloxacillin sodium [1847-24-1]; Up 200; 8.4uM; MCF7; HT_HG-U133A	HFE USP2 PLCD1 TNS1 GEM EPHA1	9.46e-05	194	86	6	6507_UP
Drug	Furaltadone hydrochloride [3759-92-0]; Up 200; 11uM; PC3; HT_HG-U133A	POMT2 PLA2G2A ZNF407 PRKCE DGCR8 PRDM14	9.73e-05	195	86	6	4313_UP
Drug	Sulfadoxine [2447-57-6]; Up 200; 12.8uM; PC3; HT_HG-U133A	HFE ZNF516 TNK2 PLCD1 MAPK7 EPHA1	1.00e-04	196	86	6	5852_UP
Drug	Tubocurarine chloride pentahydrate (+) [6989-98-6]; Down 200; 5.2uM; MCF7; HT_HG-U133A	POMT2 HFE ZNF136 SLC11A2 PRKCE DGCR8	1.03e-04	197	86	6	5449_DN
Drug	Sulpiride [15676-16-1]; Up 200; 11.8uM; PC3; HG-U133A	HFE TNK2 DGCR8 MAPK7 FBXL2 PRDM14	1.03e-04	197	86	6	1887_UP
Drug	Sulfachloropyridazine [80-32-0]; Up 200; 14uM; HL60; HT_HG-U133A	TAOK2 HFE ZFR2 TNK2 FBXL2 ZBTB1	1.03e-04	197	86	6	2191_UP
Drug	LY 294002; Up 200; 0.1uM; HL60; HT_HG-U133A	HFE USP2 TNK2 PLCD1 DGCR8 MAPK7	1.03e-04	197	86	6	2676_UP
Drug	Hesperidin [520-26-3]; Up 200; 6.6uM; PC3; HT_HG-U133A	TAOK2 HFE ZBTB7A NPY5R TNK2 CRTAC1	1.03e-04	197	86	6	6714_UP
Drug	Homatropine hydrobromide (R,S) [51-56-9]; Down 200; 11.2uM; MCF7; HT_HG-U133A	HFE ZBTB7A NPY5R BRAF TNK2 FBXL2	1.03e-04	197	86	6	5477_DN
Drug	Viomycin sulfate [37883-00-4]; Up 200; 5.2uM; PC3; HT_HG-U133A	TAOK2 POMT2 DGCR8 ZBTB1 NIPBL BRWD1	1.06e-04	198	86	6	7278_UP
Drug	Tolbutamide [64-77-7]; Down 200; 14.8uM; MCF7; HT_HG-U133A	TAOK2 HFE ZNF134 ZBTB7A FBXL2 EPHA1	1.06e-04	198	86	6	2320_DN
Drug	2-propylpentanoic acid; Down 200; 1000uM; MCF7; HG-U133A	HFE ZNF516 CHEK1 OGDH TNS1 ZBTB1	1.06e-04	198	86	6	23_DN
Drug	Zuclopenthixol hydrochloride [633-59-0]; Up 200; 9.2uM; HL60; HT_HG-U133A	TAOK2 HFE PLA2G2A TNK2 PRKCE ZNF614	1.09e-04	199	86	6	2936_UP
Drug	Diltiazem hydrochloride [33286-22-5]; Down 200; 8.8uM; HL60; HG-U133A	DGCR8 HACD2 OGDH ZBTB1 NIPBL DNMT1	1.09e-04	199	86	6	2032_DN
Drug	Dioxybenzone [131-53-3]; Up 200; 16.4uM; MCF7; HT_HG-U133A	HFE ZNF134 ZNF407 PRKCE DGCR8 TNS1	1.09e-04	199	86	6	6478_UP
Drug	Leucomisine [17946-87-1]; Up 200; 16.2uM; PC3; HT_HG-U133A	POMT2 ZBTB7A ZNF407 ZNF749 MAPK7 FBXL2	1.09e-04	199	86	6	7125_UP
Drug	Clioquinol [130-26-7]; Down 200; 13uM; MCF7; HT_HG-U133A	TAOK2 ZBTB7A NPY5R PC ZBTB1 EPHA1	1.09e-04	199	86	6	5623_DN
Drug	Laudanosine (R,S) [1699-51-0]; Down 200; 11.2uM; MCF7; HT_HG-U133A	POMT2 ZBTB7A SLC11A2 DGCR8 FBXL2 PC	1.09e-04	199	86	6	2890_DN
Drug	Selegiline hydrochloride [14611-52-0]; Up 200; 17.8uM; PC3; HT_HG-U133A	HFE ZNF516 PLCD1 DGCR8 ZNF225 TNS1	1.09e-04	199	86	6	4065_UP
Drug	Fluvoxamine maleate [61718-82-9]; Down 200; 9.2uM; HL60; HT_HG-U133A	SLC11A2 BRAF DGCR8 ZNF225 NIPBL ZNF614	1.09e-04	199	86	6	2913_DN
Drug	Iobenguane sulfate; Down 200; 10.8uM; MCF7; HT_HG-U133A	HFE PLCD1 DGCR8 MAPK7 ZNF282 EPHA1	1.09e-04	199	86	6	2878_DN
Drug	Khellin [82-02-0]; Up 200; 15.4uM; MCF7; HT_HG-U133A	TAOK2 POMT2 HFE ZNF134 PLCD1 NIPBL	1.12e-04	200	86	6	1504_UP
Drug	Carbachol [51-83-2]; Down 200; 21.8uM; MCF7; HT_HG-U133A	TAOK2 HFE ZBTB7A PLCD1 MAPK7 ZBTB1	1.12e-04	200	86	6	3380_DN
Drug	auramycinone	AKNA ARAF	1.40e-04	5	86	2	CID000196523
Drug	AC1NQZIH	AKNA ARAF	1.40e-04	5	86	2	CID005282121
Disease	cancer (implicated_via_orthology)	BRAF HACD2 MAP2K2 NIPBL HACD1 ARAF	1.19e-04	268	84	6	DOID:162 (implicated_via_orthology)
Disease	Turner Syndrome, Male	BRAF MAP2K2	4.33e-04	11	84	2	C0041409
Disease	Female Pseudo-Turner Syndrome	BRAF MAP2K2	4.33e-04	11	84	2	C1527404
Disease	Noonan Syndrome 1	BRAF MAP2K2	4.33e-04	11	84	2	C4551602
Disease	Hereditary hemochromatosis	HFE SLC11A2	5.19e-04	12	84	2	C0392514
Disease	Hemochromatosis	HFE SLC11A2	5.19e-04	12	84	2	C0018995
Disease	Malignant neoplasm of liver	SLC11A2 BRAF TNK2 PRKCE	7.36e-04	142	84	4	C0345904
Disease	Liver neoplasms	SLC11A2 BRAF TNK2 PRKCE	7.36e-04	142	84	4	C0023903
Disease	low density lipoprotein cholesterol measurement, physical activity	HFE APOB OGDH	8.95e-04	66	84	3	EFO_0003940, EFO_0004611
Disease	Alcohol abuse	HFE GABRG2 NPY5R	9.35e-04	67	84	3	C0085762
Disease	Noonan-Like Syndrome With Loose Anagen Hair	BRAF MAP2K2	1.33e-03	19	84	2	C3501846
Disease	Costello syndrome (disorder)	BRAF MAP2K2	1.33e-03	19	84	2	C0587248
Disease	Noonan syndrome-like disorder with loose anagen hair	BRAF MAP2K2	1.33e-03	19	84	2	C1843181
Disease	Cardio-facio-cutaneous syndrome	BRAF MAP2K2	1.33e-03	19	84	2	C1275081
Disease	LEOPARD Syndrome	BRAF MAP2K2	1.78e-03	22	84	2	C0175704
Disease	Noonan Syndrome	BRAF MAP2K2	2.12e-03	24	84	2	C0028326
Disease	epiandrosterone sulfate measurement	ZBTB7A MAP2K2	2.30e-03	25	84	2	EFO_0021120
Disease	Alzheimer disease, high density lipoprotein cholesterol measurement	APOB EPHA1	2.49e-03	26	84	2	EFO_0004612, MONDO_0004975
Disease	Adenocarcinoma of large intestine	BRAF TBCK ARAF	2.63e-03	96	84	3	C1319315
Disease	Colorectal cancer	BRAF PLA2G2A	2.68e-03	27	84	2	cv:C0346629
Disease	COLORECTAL CANCER	BRAF PLA2G2A	2.68e-03	27	84	2	114500
Disease	Neoplasm of the large intestine	BRAF PLA2G2A	2.68e-03	27	84	2	cv:C0009404

Protein segments in the cluster

Peptide	Gene	Start	Entry
RMKRYILHFHSAGLD	EPHA1	926	P21709
AQGMDYLHAKSIIHR	BRAF	561	P15056
MLNHENVVKFYGHRR	CHEK1	61	O14757
MARKLRYTHHDRKNG	DNMT1	1451	P26358
YQILHECLKRNHGMG	DGCR8	621	Q8WYQ5
MIKRHRAACLIQAHY	ASPM	3026	Q8IZT6
MHSLDHRNLIRLYGV	TNK2	181	Q07912
LALQRHKHHMGTRYI	ESRP1	281	Q6NXG1
LAYLREKHQIMHRDV	MAP2K2	181	P36507
HHRGVALLARAMVQY	MROH7	941	Q68CQ1
LMVQKEPHQYSHRNR	GEM	31	P55040
LQAHGNLVNFHRMIK	PLA2G2A	16	P14555
LLRGLKYMHSAQVIH	MAPK7	166	Q13164
RMRAQLPHVKVHAYF	FBXL2	386	Q9UKC9
RRRVHQVNGHKFMAT	PRKCE	161	Q02156
AAHYVHRNPKLMLRR	PLXNB3	1431	Q9ULL4
LCSHLYSMIRGNRQH	NIPBL	2391	Q6KC79
PHNMYLHSALVKSRQ	SLC11A2	266	P49281
QEMGHRRAIHLITNY	IRAK3	91	Q9Y616
RHGRGFNARYKMLIH	GLIS2	211	Q9BZE0
QGRLLRSHSLHYLFM	HFE	21	Q30201
RSHSMIHYNPRDKQL	OLFML1	366	Q6UWY5
LKQGYRHVHLMSKNG	PLCD1	726	P51178
DVKYHLGMYHRRINR	OGDH	346	Q02218
GMDYLHAKNIIHRDL	ARAF	416	P10398
PKSLHMYANRLLDHR	APOB	1201	P04114
MVGHKNEHARRYLSK	CDC16	311	Q13042
YGLRSLTRLHMDHNN	IGSF10	126	Q6WRI0
GKTAQYRQEMRHLHQ	CEP89	681	Q96ST8
LYFHMLRQRRKVLHG	HACD1	266	B0YJ81
QLYFHMIHQRRKILS	HACD2	231	Q6Y1H2
HGRIHIRIAKMDSYA	GABRG2	431	P18507
RLRHKELQMEQVYHG	AKNA	746	Q7Z591
DLMIRNIQLHHSGKY	CNTN6	561	Q9UQ52
IKMHRRILGHLSAVY	BRWD1	176	Q9NSI6
PHRLYLQMSTHGKVR	CRTAC1	316	Q9NQ79
GLYYIHRNKILHRDM	CDK9	136	P50750
MRQKHYLEAAARGLH	C18orf21	1	Q32NC0
GIMTRFLYQHKQSHR	CNTNAP5	1256	Q8WYK1
IQERHNGYDPRTMKH	CKMT1A	126	P12532
IVNYMKTRHQRGDTH	GTF2E2	81	P29084
KRHLPRQMHVSSVDY	SYT6	176	Q5T7P8
LHKMAEANRALAHYR	MRPS7	226	Q9Y2R9
TRQMHNGTHVVRHYK	STAP2	191	Q9UGK3
HGRLTKRYMQEHGYL	TRIM42	211	Q8IWZ5
LNKHMRVHSGDRPYQ	PRDM14	476	Q9GZV8
KNLRMAIGYLHSHRH	POMT2	346	Q9UKY4
AIVRYHMIKHPISNN	NPY5R	136	Q15761
CAVLYSNHNRMGRHK	NEPRO	66	Q6NW34
IDQLMAHSHLRYKGT	SMG9	391	Q9H0W8
LKTVHERQHGHRQYM	MRRF	31	Q96E11
LQGLAYLHSHNMIHR	TAOK2	136	Q9UL54
HKQLMLESIIRGLYH	MROH2B	1341	Q7Z745
MHNIPVYKDITHGNR	MRPL49	91	Q13405
TLLAKRRYMRQHLDH	L3HYPDH	46	Q96EM0
GKIFRTYHQMVLHSR	ZNF516	521	Q92618
LNVHRKMHTGERPYR	ZNF793	326	Q6ZN11
YVKARLIEHQRMHSG	ZNF157	396	P51786
QHALRMLAFRQTHKV	ZFR2	881	Q9UPR6
MYNSKLIRHQKVHTG	ZNF749	336	O43361
TLNMHQRVHAGKRLY	ZNF749	396	O43361
YKHRGRNLRSHMLER	ZNF136	56	P52737
QQLEHKFGRMRRHYL	TSPYL1	251	Q9H0U9
EAYRKRMHQLLQALH	RASGEF1C	146	Q8N431
YVLQRLKVHMRTHNG	ZNF410	261	Q86VK4
REKQGAMYHTQHLRS	TNS1	451	Q9HBL0
NLTQHQRMHRGKKVY	ZNF660	176	Q6AZW8
LQGLQYMNKHGIVHR	TBCK	101	Q8TEA7
NLRKDMRSHYNAKHL	ZBTB1	696	Q9Y2K1
LRIHQRVHMGEKLYN	ZNF225	191	Q9UK10
LNSHRMVHTGEKRYK	ZNF225	331	Q9UK10
RYNSKLIRHQMSHTG	ZNF621	161	Q6ZSS3
GFKQQYALMRHRRTH	ZNF319	351	Q9P2F9
KNHMRIHTGVRPYQC	ZBTB7C	436	A1YPR0
KYNSRLVQHKIMHTG	ZFP62	151	Q8NB50
LIQHQRMHTGERPYK	ZNF354A	481	O60765
AFSVNGKLMRHQRIH	ZNF23	456	P17027
DARNHVKRHLGMREY	ZNF407	1581	Q9C0G0
LIQHQRMHTGERPYK	ZNF354B	481	Q96LW1
GFTMKRYLVVHQRTH	ZNF614	351	Q8N883
LQRLYMRDLHHGSNA	USP2	296	O75604
HSIRTLAMHRNAYKR	XKRX	156	Q6PP77
RAQKLLHYLGHVMVN	PC	496	P11498
NLTQHKRIHTGEMPY	ZNF134	246	P52741
LIRHQMTHRGERPYK	ZNF282	561	Q9UDV7
YDLKNHMRVHTGLRP	ZBTB7A	451	O95365
CGKNIIYHSSIQRHM	ZNF439	191	Q8NDP4
GKSFRQGMHLTRHQR	ZNF263	581	O14978